A MESSAGE TO ALL OUR HEALTHCARE PARTNERS AND WIDER COMMUNITIES (COVID-19)

learn more

Resources

Please access the following materials to learn more about using the APO-go® PEN and APO-go® INFUSION devices

Setting up the APO-Go Pen: A guide for HCPs

Setting up the Crono APO-GO III Pump in APO1 Mode: A guide for HCPs

Setting up the Crono APO-Go III Pump in APO3 Mode: A Guide for HCPs

  1. 1. Parkinson’s and You. A guide for people new to the condition. https://www.parkinsons.org.uk/sites/default/files/2018-09/B181%20Parkinson%27s%20and%20you%20WEB.pdf. Accessed 20 Nov 2020.
  2. SmPC: APO-go Pen 10mg/ml Solution for Injection. https://www.medicines.org.uk/emc/product/2232/smpc. Accessed 20 Nov 2020.
  3. 3. SmPC: APO-go PFS 5mg/ml Solution for Infusion in Pre-filled Syringe. https://www.medicines.org.uk/emc/product/3908/smpc. Accessed 20 Nov 2020.
  4. 4. Antonini A & Jenner P. Apomorphine infusion in advanced Parkinson disease. Nat Rev Neurol. 2018;14:693-94.
  5. 5. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurology 2003;2:107–16
  6. 6. Fasano A, Visanji NP, Liu LWC, et al. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 2015;14:625-39.
  7. 7. Stocchi F. The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerations. Exp Opin Pharmacother 2006;7:1399-407.
  8. 8. Chapuis S, Ouchchane L, Metz O, et al. Impact of the motor complications of Parkinson’s disease on the quality of life. Mov Disord. 2005;20:224-30.
  9. 9. Trenkwalder C, Chaudhuri KR, García Ruiz PJ, et al. on behalf of an Expert Consensus Group for the use of apomorphine in Parkinson's disease. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease - clinical practice recommendations. Parkinsonism Rel Disord 2015;21:1023-30.
  10. 10. Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol. 2001;58:1385-92.
  11. 11. Pfeiffer RF, Gutmannb L, Hull KL Jr, et al., the APO302 Study Investigators. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson’s disease. Parkinsonism Rel Disord 2007;13:93–100.
  12. 12. Katzenschlager R, Poewe W, Rascol O, et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2018;17:749-59.
  13. 13. Silverdale M. Continuous dopaminergic stimulation in Parkinson’s disease. Prog Neurol Psychiatr 2007;11:24-8.
  14. 14. Pietz K, Hagell P, Odin P. J Neurol Neurosurg Psychiatry 1998;65:709–716.
  15. 15. Kanovsky P, et al. Mov Disord 2002;17(1):188–191.

Close

AM IMPAKT Study interim results. Presented at International Parkinson and Movement Disorder Society. Treatment of Parkinson’s Disease: Past, Present and Future. March 2014, Miami, Florida, USA.
Antonini A, et al. Parkinsonism and Relat Disord 2009;15S:S97-S100.
APO-go PEN SmPC
APO-go PFS SmPC
Chaudhuri KR, Ondo W. Handbook of Movement Disorders, Current Medicine Group, 2009.
Deleu D, Hanssens Y, Northway MG. Drugs and Aging 2004;21(11):687–709.
Dewey et al. Arch.Neurol 2001;58(9):1385–92.
Drapier S, et al.Parkinsonism and Relat Disord 2012;18:40-44.
Hagell P, Odin P. J Neurosci Nurs 2001;33(1):21–38.
NICE Guidelines for Parkinson’s Disease: National clinical guidelines for diagnosis and management in primary and secondary care. Royal College of Physicians, published June 2006.
Pietz K, Hagell P, Odin P. J Neurol Neurosurg Psychiatry 1998;65(5):709–16.
Riederer P et al. Parkinsonism Relat Disord 2007;13(8):466–79.
Rizos A, et al. Poster presented at MDPD, Seoul, 2013.
Ruiz PJG, et al. Movement Disord 2008;23(8):1130-1136.
Silverdale M. Continuous dopaminergic stimulation in Parkinson’s disease. Progress in Neurology and Psychiatry .2007;11(1):24-28.
Stacy M. J Neural Transm 2010;117:837-846.
Stocchi F. Neurol Sci 2008;29:S383-S386.
Todd A, James C-A. Apomorphine nodules in Parkinson’s disease: Best Practice management. British Journal of Community Nursing, Clinical Review 2008;13(10):457-63.
Bhidayasiri R, Chaudhuri K R, LeWitt P, et al. Clin Neuropharm 2015;38:89–103.

Parkinson’s UK Website. https://www.parkinsons.org.uk/content/parkinsons-symptoms.

Prescribing Information Report an adverse event References